VSEE EBITDA | VSee Health, Inc.

VSee Health, Inc. (VSEE) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$2.70M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.97M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.06M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.56M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$2.70M	(m)	$1.56M	(m)	$73.25K*	-$1.17M*	(m)	(m)	(m)	-$17.90K
2026-03-31	Reported	(m)	-$2.97M	(m)	$3.16M	(m)	$26.75K	-$2.45M	(m)	(m)	(m)	$23.74K
2025-09-30	Reported	(m)	-$2.06M	(m)	$3.98M	(m)	$22.78K*	-$754.54K*	(m)	(m)	(m)	$0.00
2025-06-30	Reported	(m)	-$1.56M	(m)	$1.06M	(m)	-$11.87K*	-$324.60K*	(m)	(m)	(m)	$1.73K
2025-03-31	Reported	(m)	-$1.83M	(m)	$3.32M	(m)	$11.87K	-$440.49K	(m)	(m)	(m)	$13.51K
2024-09-30	Reported	(m)	-$58.29M	(m)	$3.35M	(m)	$4.99K*	-$221.03K*	$941.39K	(m)	(m)	$8.80K
2024-06-30	Reported	(m)	-$932.52K	(m)	$1.71M	(m)	$36.77K*	-$3.17M*	$486.64K	(m)	(m)	-$1.68M
2024-03-31	Reported	(m)	$104.06K	(m)	$1.62M	(m)	$8.74K	$579.29K	(m)	(m)	(m)	$0.00
2023-09-30	Reported	(m)	-$353.07K	(m)	$1.43M	(m)	$0.00*	-$48.79K*	$478.40K	(m)	(m)	-$233.72K
2023-06-30	Reported	(m)	-$689.84K	(m)	$1.27M	(m)	(m)	-$133.98K*	$474.29K	(m)	(m)	-$174.40K
2023-03-31	Reported	(m)	-$715.86K	(m)	$1.58M	(m)	(m)	-$340.67K	(m)	(m)	(m)	(m)
2022-09-30	Reported	(m)	-$1.13M	(m)	(m)	(m)	(m)	-$146.16K*	(m)	(m)	(m)	$83.03K
2022-06-30	Reported	(m)	-$722.16K	(m)	(m)	(m)	(m)	-$318.60K*	(m)	(m)	(m)	$0.00
2022-03-31	Reported	(m)	-$543.18K	(m)	(m)	(m)	(m)	-$250.29K	(m)	(m)	(m)	(m)
2021-09-30	Reported	(m)	-$180.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Reported	(m)	-$5.00K	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$9.58M	(m)	$14.62M	(m)	$29.93K	-$3.45M	(m)	(m)	(m)	$13.51K
2024-12-31	Reported	(m)	-$62.15M	(m)	$10.42M	(m)	$55.27K	-$5.79M	(m)	(m)	(m)	-$1.64M
2023-12-31	Reported	(m)	-$1.87M	(m)	$5.77M	(m)	$4.33K	-$632.60K	(m)	(m)	(m)	$1.84M
2022-12-31	Reported	(m)	-$3.59M	(m)	(m)	(m)	(m)	-$1.39M	(m)	(m)	(m)	$187.22K

Stock Name	Country	Market Cap	PE Ratio
Agape ATP Corp (ATPC)		$0.002B
DocGo Inc. (DCGO)	United States	$0.034B	-0.25
Strata Critical Medical, Inc. (SRTA)	United States	$0.467B	11.33
InnovAge Holding Corp. (INNV)	United States	$1.206B	-635.60
Omada Health, Inc. (OMDA)	United States	$1.207B	309.08
U S PHYSICAL THERAPY INC /NV (USPH)	United States	$1.251B	32.48
Pennant Group, Inc. (PNTG)	United States	$1.386B	39.84
Privia Health Group, Inc. (PRVA)	United States	$2.477B	115.52
GeneDx Holdings Corp. (WGS)	United States	$2.638B	-19.23
LifeStance Health Group, Inc. (LFST)	United States	$4.510B	80.86